Skip to main content
Publications
Herring W, Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Herring W, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Didden E-M, Andrews EB, Hellwig K, Hernandez-Diaz S, Magyari M, Margulis AV, Rivero-Ferrer E, Bader-Weder S, Wormser D. A novel approach for active surveillance of pregnancy safety in multiple sclerosis. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):268. doi: 10.1002/pds.4629
Peay H, Fischer R, Beaverson K, Morris C, Hesterlee SE, Ricotti V, Martin A, Rensch C, Wand H, Mansfield CA. Parent and adult patient attitudes about gene therapy as a therapeutic option for Duchenne Muscular Dystrophy. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S256.
Margulis A, Andrews E, Hernandez-Diaz S, Magyari M, Rivero-Ferrer E, Bader-Weder S, Evershed J, Garas M, Wang Q, Wormser D. Design of a multi-source post-marketing study to evaluate pregnancy and infant outcomes in women with multiple sclerosis who were exposed to ocrelizumab during, or within 6 months before, pregnancy. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 25, 2018. Los Angeles, CA.